Horizon Investments LLC raised its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 74.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 139,641 shares of the company's stock after buying an additional 59,618 shares during the quarter. Horizon Investments LLC's holdings in AbbVie were worth $31,652,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the business. Robertson Stephens Wealth Management LLC lifted its stake in AbbVie by 118.2% in the fourth quarter. Robertson Stephens Wealth Management LLC now owns 63,218 shares of the company's stock valued at $14,445,000 after buying an additional 34,246 shares during the period. Fifth Third Bancorp lifted its stake in AbbVie by 0.8% in the fourth quarter. Fifth Third Bancorp now owns 1,491,171 shares of the company's stock valued at $340,718,000 after buying an additional 12,110 shares during the period. Mutual Advisors LLC lifted its stake in AbbVie by 2.1% in the fourth quarter. Mutual Advisors LLC now owns 34,452 shares of the company's stock valued at $7,872,000 after buying an additional 705 shares during the period. Uptick Partners LLC lifted its stake in AbbVie by 27.5% in the fourth quarter. Uptick Partners LLC now owns 1,702 shares of the company's stock valued at $389,000 after buying an additional 367 shares during the period. Finally, Payne Capital Management LLC lifted its stake in AbbVie by 7.1% in the fourth quarter. Payne Capital Management LLC now owns 1,151 shares of the company's stock valued at $263,000 after buying an additional 76 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.
More AbbVie News
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
- Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
- Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
- Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
- Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
- Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
- Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary
Insider Buying and Selling at AbbVie
In related news, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company's stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.06% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the company. Bank of America raised AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 price target on the stock in a research note on Thursday. Citigroup dropped their price target on AbbVie from $235.00 to $230.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 27th. Piper Sandler dropped their price target on AbbVie from $299.00 to $294.00 and set an "overweight" rating on the stock in a research note on Thursday, April 23rd. Morgan Stanley boosted their price target on AbbVie from $270.00 to $278.00 and gave the company an "overweight" rating in a research note on Thursday. Finally, DZ Bank raised AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Thursday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $252.90.
View Our Latest Research Report on ABBV
AbbVie Stock Down 2.2%
NYSE ABBV opened at $206.63 on Friday. The company has a market cap of $365.36 billion, a price-to-earnings ratio of 101.79, a P/E/G ratio of 0.76 and a beta of 0.38. AbbVie Inc. has a 52 week low of $176.57 and a 52 week high of $244.81. The business has a 50 day moving average price of $214.55 and a 200-day moving average price of $221.60.
AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The firm had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the previous year, the company posted $2.46 earnings per share. The company's quarterly revenue was up 12.4% on a year-over-year basis. On average, equities research analysts anticipate that AbbVie Inc. will post 14.21 earnings per share for the current year.
AbbVie Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie's dividend payout ratio is 340.89%.
About AbbVie
(
Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
